IKK- alpha/ beta (Phospho-Ser176/177) Antibody

Catalog No: #11931

Package Size: #11931-1 50ul #11931-2 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	IKK- alpha/ beta (Phospho-Ser176/177) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Applications	WB,IHC,IF,ELISA
Species Reactivity	Human;Mouse;Rat
Specificity	The antibody detects endogenous level of IKK- alpha/beta only when phosphorylated at serine 176/177.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of serine 176/177 (Q-G-S(p)-L-C) derived from Human IKK-alpha/beta.
Conjugates	Unconjugated
Target Name	IKK- alpha/ beta
Modification	Phospho
Other Names	FLJ40509; I-kappa-B kinase; IKBKB; kinase beta; NFKBIKB
Accession No.	Swiss-Prot#: O15111/O14920; NCBI Gene#: 1147; NCBI Protein#: NP_001269.3
SDS-PAGE MW	85kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C/1 year

Application Details

WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:10000; IF 1:50-200

Images



All Lanes:IKK- alpha/ beta (Phospho-Ser176/177) Antibody at 1/ 500 dilution.Lane1:Jurkat treated with 20ng/ml TNF-α for 30min Cell lysateLane2: Huvec treated with 100ng/ml EGF for 30min Cell lysateLane3: Hela treated with 100ng/ml EGF for 30min Cell lysateLane4: HepG2 treated with 100ng/ml EGF for 30min Cell lysateLane5: Mouse Brain Tissue lysateLane6:Mouse lung Tissue lysateLane7:Rat Liver Tissue lysateLysates/proteins at 40 µg per lane. Secondary: Goat Anti-Rabbit IgG(HRP) at 1/20000 dilutionPredicted band size : 85kDaObserved band size:B 80kDa

Background

Acts as part of the IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. Also phosphorylates NCOA3.

Chandrakesan P, et al. (2010)J Biol Chem 285, 33485-98

Hinz M, et al. (2010£© Mol Cell 40, 63-74

Choudhary S, Lu M, Cui R, Brasier AR (2007)Mol Endocrinol 21, 2203-17

Published Papers

Ying Wan;Li Han;Lu Rong;Shuyuan Yang;Lu Song;Na Wu;Zhenguo Liu;Jing Gan el at., Inhibition of BET Protein Function Suppressed the Overactivation of the Canonical NF-κB Signaling Pathway in 6-OHDA-Lesioned Rat Model of Levodopa-Induced Dyskinesia, , (2022)

PMID:35801173

Note: This product is for in vitro research use only and is not intended for use in humans or animals.